Journal ArticleDOI
A Low-Dose Antimony Treatment in 159 Patients with American Cutaneous Leishmaniasis: Extensive Follow-up Studies (Up to 10 Years)
M. P. Oliveira-Neto,Armando de Oliveira Schubach,Marise Mattos,S. C. Goncalves-Costa,Claude Pirmez +4 more
Reads0
Chats0
TLDR
The results show that a low dose of antimony is less toxic, more appropriate, especially in children and elderly people, and has the same final result as that obtained with larger doses.Abstract:
The efficacy of an antimony regimen at the dose of 20 mg/kg/day for a 3-4-week period is well established in the treatment of American cutaneous leishmaniasis. Several drug side effects, however, have been described and the search for more suitable regimens is advisable. In the present paper, the effect of a low dose (5 mg/kg/day for 30 days) of antimony was evaluated in 159 individuals from endemic regions of Rio de Janeiro State, Brazil, an area of Leishmania (V.) braziliensis transmission. Patients presented typical cutaneous lesions and parasites were demonstrated in all cases. One hundred forty-three patients were available for evaluation and of these, 120 (84%) were cured by the end of therapy. Twenty-three patients (16%) were considered treatment failures. Side effects were observed in only six patients (4%). Extensive follow-up (up to 10 years) disclosed no relapses or mucosal lesions. The results show that a low dose of antimony is less toxic, more appropriate, especially in children and elderly people, and has the same final result as that obtained with larger doses.read more
Citations
More filters
Journal ArticleDOI
Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis
TL;DR: A critical review of the diagnostic methods, their contribution and the necessity for their improvement/development are presented, particularly in molecular diagnosis aimed at detection and species identification, as well as serodiagnosis.
Journal ArticleDOI
Miltefosine for New World Cutaneous Leishmaniasis
Jaime Soto,Byron Arana,J. Toledo,Nidia Rizzo,J. Vega,Anaite Diaz,M. Luz,Patricia Gutierrez,Margarita Arboleda,Jonathan Berman,Klaus Junge,J. Engel,H. Sindermann +12 more
TL;DR: It is shown that miltefosine is a useful oral agent against cutaneous leishmaniasis due to L. v. panamensis in Colombia but not against leish maniasis dueto L. braziliensis in Guatemala.
Journal ArticleDOI
Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
Luiz Filipe Gonçalves de Oliveira,Armando de Oliveira Schubach,Maria de Fátima Moreira Martins,Sonia Regina Lambert Passos,Raquel de Vasconcellos Carvalhaes de Oliveira,Mauro Célio de Almeida Marzochi,Carlos Augusto Ferreira de Andrade +6 more
TL;DR: Although closer surveillance is needed for the treatment of cutaneous leishmaniasis, antileishmanial drugs are basically safe and severe side effects requiring the discontinuation of treatment are relatively uncommon.
Journal ArticleDOI
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)
Naomi E. Aronson,Barbara L. Herwaldt,Michael Libman,Richard D. Pearson,Rogelio López-Vélez,Peter J. Weina,Edgar M. Carvalho,Moshe Ephros,Selma M. B. Jeronimo,Alan J. Magill +9 more
TL;DR: It is important to realize that leishmaniasis guidelines cannot always account for individual variation among patients, and that adherence to these guidelines to be voluntary.
Journal ArticleDOI
Treatment of cutaneous leishmaniasis among travellers
TL;DR: An overview of published treatment options and a treatment recommendation is given for each of the most important species and the level of evidence of the studies leading to these recommendations is given.